Navigation Links
NAMS issues new guidance on vulvovaginal atrophy
Date:8/28/2013

CLEVELAND, Ohio (August 29, 2013)Symptoms of vulvovaginal atrophy (VVA), such as lack of lubrication, irritated tissues, painful urination, and pain with intercourse, affect as many as 45% of women after menopause. That's according to The North American Menopause Society (NAMS), which today published new guidance for diagnosing and treating VVA. The Society's Position Statement "Management of Vulvovaginal Atrophy" appears in the September issue of Menopause.

"The symptoms of VVA can significantly impair women's quality of life and relationships, yet few women whose lives are affected get help. This new Position Statement gives clinicians the information they need to address these problems," says Margery Gass, MD, the Society's Executive Director.

The Position Statement explains that bothersome symptoms can be treated successfully, and many treatments are available, ranging from over-the-counter products to prescription hormonal and nonhormonal products. Which therapy to use depends on how severe the symptoms are, whether the therapy is safe and effective for the individual woman, and what she prefers.

Simple vaginal lubricants and moisturizers along with regular intercourse (or use of vaginal dilators) can be effective and are considered first-line therapy by NAMS. When these are not effective, estrogen, either applied locally or as part of systemic hormone therapy, remains the therapeutic standard. A nonhormonal option, the selective estrogen-receptor modulator ospemifene, was recently approved for moderate to severe painful intercourse.

For hormonal therapy, low-dose vaginal estrogen is the preferred approach when VVA symptoms are the only bothersome menopausal symptoms a woman has. Generally, women who use a vaginal estrogen do not need to take a progestogen to protect the uterus if they have not had a hysterectomy.

For a woman who is a survivor of breast or endometrial cancer, the choice of treatment depends on her preferences, needs, understanding of potential risks, and consultation with her oncologist.


'/>"/>

Contact: Eileen Petridis
epetridis@fallscommunications.com
216-696-0229
The North American Menopause Society (NAMS)
Source:Eurekalert

Related medicine news :

1. Online USA Doctors Announces a New Male Treatment Program For Sensitive Male Health Issues
2. Transvaginal Mesh Multidistrict Litigation Update: Court Issues New Pretrial Order that Moves Ethicon Inc.’s Discovery Forward, Notes Parker Waichman
3. Research examines parents use of bibliotherapy to help children struggling with social issues
4. DrugRisk Update: Court Issues Latest Decision in Pradaxa Bleeding Litigation
5. Dr. Carol Francis Talk Radio - Fifth Year Anniversary Show on "Success Tools, Professional Mental Health & Physical Fitness Advice, Social Justice Issues, Soulful Guests"
6. AED.com Issues Warning to Consumers Concerning AED Scams
7. Stryker Hip Lawsuits Proceed in New Jersey Litigation as Court Issues New Case Orders, Reports Wright & Schulte
8. Medicationdiscountcard.com Issues Advisory: Health Insurance Plans Do Not Cover Many Common Prescription Medications
9. Search Technologies Issues New White Paper Summarizing the Top Ten Applications for the Google Search Appliance
10. Da Vinci Surgical Robot Update: FDA Issues Class 2 Recall of Intuitive Surgical’s da Vinci Robot due to Possibly Inadequate Testing of 30 Units, Notes Parker Waichman LLP
11. AAPCC Issues Statement on Decision of Procter & Gamble to Redesign Tide Pods Packaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... RawTrition now brings ... way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients to ... cellular level because the body recognizes its raw form (unlike the synthetically made options ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, ... to announce that it has received 510(k) clearance from the U.S. Food & ... the MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition Duchenne, ... Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on ... clinical trial in Duchenne announced today. , Coalition Duchenne funded studies carried ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology: